Core Narrative - The healthcare sector is experiencing a decline, presenting potential investment opportunities for those willing to take on individual stock risks, particularly with the rise of Ozempic, a weight loss treatment that has gained significant traction in American households [1][2]. Group 1: Investment Opportunities - Companies like Hims & Hers Health Inc. and Eli Lilly and Co. are positioned to benefit from the Ozempic trend, with Hims & Hers focusing on a subscription model that provides stable growth and downside protection [4][10]. - The Health Care Select Sector SPDR Fund offers a diversified investment approach for those hesitant to invest in individual stocks, showing a performance gap of approximately 26% compared to the S&P 500 [6][7]. Group 2: Company Analysis - Hims & Hers Health - Hims & Hers has a gross profit margin of 76.2%, comparable to software companies, and is viewed positively by some institutions, including Nomura Holdings, which invested $8 million [11][12]. - The stock is currently priced at $43.48, with a price target of $38.92, indicating potential for growth despite being primarily associated with weight loss [8][9]. Group 3: Company Analysis - Eli Lilly - Eli Lilly has a market capitalization of $663 billion, providing it with the resources to scale effectively in the competitive landscape of weight loss products [13]. - Analysts have a consensus view of a Moderate Buy for Eli Lilly, with a price target of $950.17, suggesting a potential rally of 35.8% from its current trading price [14][15].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. spans from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements made by the defendants about the company's business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, which has resulted in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline for lead plaintiff applications set for August 25, 2025 [1]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding the promotion of knockoff versions of Wegovy that jeopardized patient safety [2][3]. - Following the announcement of the termination of the partnership by Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [3]. Group 2: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - Hims & Hers is facing a securities class action lawsuit due to allegations of misleading statements regarding its GLP-1 weight-loss drug business and a partnership with Novo Nordisk that was abruptly terminated [1][4][5] Group 1: Lawsuit Details - The class action lawsuit represents investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, alleging violations of the Securities Exchange Act of 1934 [3] - The lawsuit claims that Hims & Hers and its executives made false and misleading statements to investors, particularly concerning the partnership with Novo Nordisk [3][4] - The deadline for investors to apply as Lead Plaintiff is August 25, 2025 [2][3] Group 2: Allegations of Misconduct - The core allegations involve Hims & Hers' deceptive promotion and sale of "illegitimate, knockoff versions of Wegovy®," which allegedly jeopardized patient safety and led to the termination of the partnership with Novo Nordisk [4][5] - Novo Nordisk cited Hims & Hers' "deceptive promotion and selling" as the reason for ending the collaboration, which resulted in a stock price drop of over 34% on June 23, 2025 [2][5] Group 3: Investigations and Implications - The Federal Trade Commission (FTC) is investigating Hims & Hers over its advertising and subscription cancellation practices [6] - Hagens Berman is investigating whether Hims & Hers misled investors about its business practices, particularly regarding compounded weight-loss drugs and the terminated partnership [7][8] - The swift termination of the Novo Nordisk deal and the subsequent stock price collapse suggest a potential disconnect between what investors were told and the actual operations of Hims & Hers [8]

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating Hims & Hers for possible violations of federal securities laws during the Class Period from April 29, 2025, to June 22, 2025 [1]. - The investigation follows a significant drop in Hims & Hers' stock price, which fell over 34% after Novo Nordisk terminated its partnership due to unauthorized marketing and sale of compounded semaglutide drugs [2]. - A complaint has been filed alleging that Hims & Hers made material misstatements and omissions, violating federal securities laws [2]. Group 2: Legal Actions - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other affected investors [3].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2] - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, due to these deceptive practices, leading to a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 [5]

Core Viewpoint - Hims & Hers (NYSE: HIMS) is considered one of the most undervalued growth stories in the telehealth sector, with a reported Q2 revenue of $545 million, reflecting a 73% year-over-year increase, positioning the company for an annual revenue of $2.4 billion [1] Company Summary - Hims & Hers reported Q2 revenue of $545 million, which is a 73% increase compared to the previous year [1] - The company is on track to achieve an annual revenue of $2.4 billion [1] Industry Context - The telehealth industry is experiencing significant growth, with companies like Hims & Hers leading the way in terms of revenue increases and market potential [1]

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a substantial risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Investor Actions - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and selects counsel to represent the class in litigation [3]. - Investors can choose to remain absent from the class action without affecting their ability to share in any recovery [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Insights - Hims & Hers Health, Inc. (HIMS) is focused on democratizing access to personalized healthcare, particularly in underserved areas, with a subscriber base of 2.4 million and nearly 1,500 licensed providers by Q2 2025 [1][7] - The company is expanding into hormonal health, targeting menopause and low testosterone, which presents a significant market opportunity in the U.S. [2][7] - International expansion through the acquisition of ZAVA enhances Hims & Hers' presence in Europe, gaining access to over 1.3 million patients, with plans to enter Canada in 2026 [3][7] Market Performance - Hims & Hers shares have increased by 86.5% year-to-date, outperforming the industry growth of 23.5% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 3.8X, lower than the industry average of 5.8X but higher than its three-year median of 2.4X [8] Financial Estimates - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 indicates a 137% improvement from 2024 [9] - Current consensus estimates for HIMS' earnings per share are 0.12 for Q3 2025, 0.14 for Q4 2025, 0.64 for the current year, and 0.89 for the next year [12]